TY - JOUR
T1 - The association between health-related quality of life and five-year overall survival among head and neck cancer patients
T2 - A prospective cohort study
AU - Verdonck-de Leeuw, Irma M.
AU - Lissenberg-Witte, Birgit I.
AU - de Bree, Remco
AU - Buffart, Laurien M.
AU - Hardillo, Jose
AU - Lamers, Femke
AU - Langendijk, Johannes A.
AU - Leemans, C. René
AU - Takes, Robert P.
AU - Jansen, Femke
N1 - Publisher Copyright: © 2025 The Author(s)
PY - 2025/7
Y1 - 2025/7
N2 - Objective: To estimate associations between health-related quality of life (HRQOL) at baseline (T0), six months after treatment (M6), and change in HRQOL (T0-M6) and five-year overall survival (OS) among head and neck cancer (HNC) patients, after adjusting for potential confounders. Furthermore, we explored whether personal, clinical, physical, psychological, social, lifestyle, HNC-related and biological factors moderate the association. Methods: Data of a prospective multi-center cohort study (NET-QUBIC) was used. In this specific study, patients with HRQOL data at T0 (n = 596), M6 (n = 489), and T0 and M6 (n = 463) were included. HRQOL was operationalized by the EORTC QLQ-C30 global quality of life subscale (QL) and summary score (SumSc). Cox regression analyses investigated associations between HRQOL and OS, adjusted for confounders, and explored which variables moderate the association. Results: Adjusted models showed that higher baseline QL (HR: 0.85 (95% CI: 0.76–0.96)) and SumSc (HR: 0.90 (95% CI: 0.81–0.99)) were associated with longer OS. Adjusted M6 models and adjusted T0-M6 models found no such association. The association between QL and OS was moderated by sex (significant among males) and mean arterial blood pressure (BP) (significant for patients with high BP). The association between SumSc and OS was moderated by coping (significant for patients with no avoidant coping style) and systemic BP (significant for patients with normal BP). Conclusion: Higher HRQOL at baseline (how patients enter the cancer trajectory) was associated with longer OS, but (change in) HRQOL at 6 months (how they overcome cancer treatment) was not. This knowledge is important to personalize treatment plans.
AB - Objective: To estimate associations between health-related quality of life (HRQOL) at baseline (T0), six months after treatment (M6), and change in HRQOL (T0-M6) and five-year overall survival (OS) among head and neck cancer (HNC) patients, after adjusting for potential confounders. Furthermore, we explored whether personal, clinical, physical, psychological, social, lifestyle, HNC-related and biological factors moderate the association. Methods: Data of a prospective multi-center cohort study (NET-QUBIC) was used. In this specific study, patients with HRQOL data at T0 (n = 596), M6 (n = 489), and T0 and M6 (n = 463) were included. HRQOL was operationalized by the EORTC QLQ-C30 global quality of life subscale (QL) and summary score (SumSc). Cox regression analyses investigated associations between HRQOL and OS, adjusted for confounders, and explored which variables moderate the association. Results: Adjusted models showed that higher baseline QL (HR: 0.85 (95% CI: 0.76–0.96)) and SumSc (HR: 0.90 (95% CI: 0.81–0.99)) were associated with longer OS. Adjusted M6 models and adjusted T0-M6 models found no such association. The association between QL and OS was moderated by sex (significant among males) and mean arterial blood pressure (BP) (significant for patients with high BP). The association between SumSc and OS was moderated by coping (significant for patients with no avoidant coping style) and systemic BP (significant for patients with normal BP). Conclusion: Higher HRQOL at baseline (how patients enter the cancer trajectory) was associated with longer OS, but (change in) HRQOL at 6 months (how they overcome cancer treatment) was not. This knowledge is important to personalize treatment plans.
UR - https://www.scopus.com/pages/publications/105005374182
U2 - 10.1016/j.oraloncology.2025.107367
DO - 10.1016/j.oraloncology.2025.107367
M3 - Article
C2 - 40393189
AN - SCOPUS:105005374182
SN - 1368-8375
VL - 166
JO - Oral Oncology
JF - Oral Oncology
M1 - 107367
ER -